Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant vaccinia virus, vaccinia virus vector vaccine and application and preparation method of recombinant vaccinia virus

A technology of vaccinia virus vector and recombinant virus vector, which is applied in the field of bioengineering, can solve the problems of fast mutation rate, poor target nucleic acid or protein stability, lack of effective prevention or treatment of new coronavirus vaccines and drugs, etc., and achieve good stability sex, virus removal effect

Inactive Publication Date: 2021-07-23
SHENZHEN HUA YAO KANG MING BIOPHARMACEUTICAL CO LTD
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If the stability of the target nucleic acid or protein is poor and the mutation rate is fast, it will be difficult for the developed vaccine to work against the mutated new coronavirus in the future
[0008] Therefore, it is necessary to provide a recombinant vaccinia virus and vaccinia virus vector vaccine capable of preventing or treating novel coronavirus pneumonia, so as to solve the current problem of lack of effective vaccines and drugs for preventing or treating novel coronavirus pneumonia, and to contain novel coronavirus pneumonia. the spread of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant vaccinia virus, vaccinia virus vector vaccine and application and preparation method of recombinant vaccinia virus
  • Recombinant vaccinia virus, vaccinia virus vector vaccine and application and preparation method of recombinant vaccinia virus
  • Recombinant vaccinia virus, vaccinia virus vector vaccine and application and preparation method of recombinant vaccinia virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0047]The technical solutions in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Apparently, the described embodiments are only some of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in this application, all other embodiments obtained by those skilled in the art without making creative efforts belong to the scope of protection of this application.

[0048] In addition, the terms "first" and "second" are used for descriptive purposes only, and cannot be interpreted as indicating or implying relative importance or implicitly specifying the quantity of indicated technical features. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of said features. In the description of the present application, "plurality" means two or more, unless otherwise specifically defin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a recombinant vaccinia virus, a vaccinia virus vector vaccine and an application and preparation method of the recombinant vaccinia virus. The recombinant vaccinia virus comprises: a combined defect of a thymidine kinase (TK) gene and an L025 gene, and a recombinant nucleic acid sequence encoding a first nucleic acid sequence in the S gene of a novel coronavirus, the first nucleic acid sequence is inserted into the genome of the recombinant vaccinia virus. The recombinant vaccinia virus vector vaccine comprises the recombinant vaccinia virus and a pharmaceutically acceptable vector or adjuvant. The method for preparing the recombinant vaccinia virus comprises the following steps: introducing the recombinant nucleic acid sequence between a left arm and a right arm of a target gene of a genome of the vaccinia virus to obtain a recombinant shuttle vector, and transfecting the recombinant shuttle vector into a host cell to form the recombinant vaccinia virus. The invention further discloses a recombinant nucleic acid sequence for coding the novel coronavirus S protein and a recombinant virus vector.

Description

technical field [0001] The present application relates to the technical field of bioengineering, in particular to the application of multiple recombinant vaccinia viruses, vaccinia virus vector vaccines and preparation methods thereof for preventing infection by novel coronaviruses. Background technique [0002] Factors to consider when developing a vaccine include: (1) how the immune system responds to the pathogen (virus or bacteria); (2) who needs the vaccine; and (3) the best technology or strategy for developing the vaccine. According to the characteristics of different pathogens, scientists develop different types of vaccines. The types of vaccines include 4 major categories: (1) live attenuated vaccines; (2) inactivated vaccines; (3) subunit polypeptide vaccines, recombinant protein vaccines, polysaccharide and conjugate vaccines; and (4) toxoid vaccines. [0003] In recent years, scientists have devoted themselves to applying new technologies to develop vaccines. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N7/01C12N15/863C12N15/50A61K39/215A61P31/14
CPCA61K39/12A61K2039/5256A61K2039/53A61P31/14C07K14/005C12N7/00C12N15/86C12N2710/24021C12N2710/24043C12N2770/20022C12N2770/20034
Inventor 袁明
Owner SHENZHEN HUA YAO KANG MING BIOPHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com